VIVS VivoSim Labs, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1497253 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY-417.8%
TTM EPS YoY-768.6%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,897.8%
Net margin-7,605.9%
FCF margin-7,618.5%
EBITDA margin-8,771.9%
Returns
ROE-143.5%
ROA-104.7%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.50x
Interest coverage-1,001.00x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue63.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $131,000 | $144,000 |
| Cost of revenue | $0 | $5,000 |
| Gross profit | $131,000 | $139,000 |
| R&D expense | $4.19M | $5.03M |
| SG&A expense | $7.43M | $7.73M |
| Operating income | -$11.49M | -$12.62M |
| Interest expense | $12,000 | $10,000 |
| Pretax income | -$13.84M | -$2.49M |
| Income tax | $2,000 | $2,000 |
| Net income | -$13.84M | -$2.49M |
| EBITDA | -$11.27M | -$12.35M |
| EPS (basic) | -5.35 | -1.70 |
| EPS (diluted) | -5.35 | -1.70 |
| Weighted avg. shares (diluted) | 2.59M | 1.46M |
| Balance sheet | ||
| Cash & equivalents | $5.02M | $11.31M |
| Receivables | $32,000 | $30,000 |
| Inventory | $0 | $0 |
| Current assets | $6.63M | $12.13M |
| PP&E, net | $206,000 | $419,000 |
| Total assets | $7.39M | $14.65M |
| Current liabilities | $2.79M | $3.74M |
| Total liabilities | $8.48M | $4.16M |
| Shareholders' equity | -$1.10M | $10.49M |
| Shares outstanding | 2.89M | 1.90M |
| Cash flow statement | ||
| Operating cash flow | -$10.83M | -$9.46M |
| Capital expenditure | $0 | $13,000 |
| Free cash flow | -$10.83M | -$9.47M |
| Investing cash flow | $94,000 | $9.03M |
| Financing cash flow | $4.45M | $8.85M |
| Depreciation & amortization | $215,000 | $266,000 |
| Stock-based compensation | $303,000 | $532,000 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.